文献速递头颈与中枢神经肿瘤

TPF联合西妥昔单抗诱导后化放疗联合西妥昔单抗及顺铂或卡铂的随机II期EORTC试验

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
PubMed 文献 · Ann Oncol · 2017-01-01

结果显示,在足量TPF诱导化疗基础上加用西妥昔单抗导致不可接受的并发症,研究提前终止;仅34/46例完成4周期TPF-E,仅30例开始化放疗。

要点

  • 足量TPF诱导化疗加西妥昔单抗出现不可接受的并发症,研究提前终止。
  • 仅34/46例完成4周期TPF-E,仅30例开始化放疗。
  • 3例发生肠穿孔,1例死于肺炎和感染性休克,1例在开始TPF-E后12天在家死亡(死因不明)。

核心结论

  • 在足量TPF诱导化疗基础上加用西妥昔单抗导致不可接受的并发症,研究提前终止。

研究设计与样本

  • 患者接受最多4周期TPF-E诱导化疗(顺铂和多西他赛75 mg/m2第1天,5-FU 750 mg/m2/天第1-5天持续输注,西妥昔单抗负荷剂量400 mg/m2后每周250 mg/m2),预防性使用抗生素但不使用生长因子。
  • 4周期TPF-E后未进展的患者随机接受放疗(70 Gy/7周,2 Gy/次)联合每周西妥昔单抗及每周顺铂40 mg/m2或卡铂AUC 1.5 mg/ml/min。
  • 主要终点为可行性。

主要发现

  • 1例患者在开始TPF前因西妥昔单抗负荷剂量期间超敏反应未启动TPF。
  • 12例患者因毒性(6例)、医疗决策(2例)、死亡(1例)、患者拒绝(1例)、方案违背(1例)、合并症(1例)停止TPF-E诱导化疗。
  • 另有3例未随机(疾病进展1例、方案违背1例、毒性和合并症1例)。
  • 3例发生肠穿孔,1例死于肺炎和感染性休克,1例在开始TPF-E后12天在家死亡(死因不明)。
  • 每周顺铂和卡铂分别有7例和4例提前停止;放疗在顺铂组2例停止、1例中断,卡铂组4例中断。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior induction chemotherapy. METHODS: Patients with stage III/IV unresectable, squamous cell carcinoma of the head and neck received up to four cycles of TPF-E (cisplatin and docetaxel 75 mg/m2 on day 1 followed by 5-FU 750 mg/m2/day as a continuous infusion on days 1-5 plus cetuximab at a loading dose of 400 mg/m2 followed by a weekly dose of 250 mg/m2), with prophylactic antibiotics but no growth factors. Patients not progressing after four cycles of TPF-E were randomly assigned to radiotherapy (70 Gy over 7 weeks in 2 Gy fractions) and weekly cetuximab with either weekly cisplatin 40 mg/m2 or carboplatin, AUC of 1.5 mg/ml/min. Primary endpoint was feasibility. RESULTS: Forty-seven patients were recruited. One patient did not start TPF (hypersensitivity reaction during the cetuximab loading dose). Induction TPF-E was discontinued in 12 patients due to toxicity (6 patients), medical decision (2), death (1), patient refusal (1), protocol violation (1), co-morbidity (1). Three further patients were not randomized [progressive disease (1), protocol violation (1), toxicity and co-morbidity (1)]. Of particular interest are three patients who suffered from bowel perforation, one patient who died as results of pneumonia and septic shock, and a second patient who was found dead at home 12 days after starting TPF-E (cause of death unknown). Weekly cisplatin and carboplatin was stopped early in seven and four patients, respectively. Radiotherapy was stopped in two patients with cisplatin and interrupted in one patient with cisplatin and four patients with carboplatin. CONCLUSIONS: The addition of cetuximab to full dose TPF induction chemotherapy led to unacceptable complications and premature closing of the study. Only 34 out of 46 patients completed four cycles of TPF-E and only 30 started biochemoradiation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Specenier PM, Remenar E, Buter J, et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol. 2017. PMID: 28911062. doi:10.1093/annonc/mdx300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。